BiotechTubeBiotechTube
Home/Pipeline/Darolutamide (Nubeqa)

Darolutamide (Nubeqa)

Prostate Cancer

ApprovedCommercial

Key Facts

Indication
Prostate Cancer
Phase
Approved
Status
Commercial
Company
Orion Corporation

About Orion Corporation

Orion Corporation is a leading Nordic pharmaceutical company founded in 1917 and headquartered in Espoo, Finland. The company operates through three main business areas: proprietary products, specialty products, and fermion (contract manufacturing). Orion has a strong presence in neurology, oncology, and critical care, with established commercial operations across Europe and expanding global reach.

View full company profile

Therapeutic Areas

OncologyNeurologyCritical CareParkinson's DiseaseSedation

Other Prostate Cancer Drugs

DrugCompanyPhase
Erleada (apalutamide)Johnson & JohnsonApproved
Nubeqa (darolutamide)BayerApproved
Xtandi (enzalutamide)Astellas PharmaApproved
Proxalutamide (HS-10370)Hansoh PharmaPhase 3
Relacorilant + EnzalutamideCorcept TherapeuticsPhase 2
NBTXR3NanobiotixPhase 1/2
Praluzatamab ravtansine (CX-2009)CytomX TherapeuticsPhase 1/2
Bavdegalutamide (ARV-110)ArvinasPhase 2
ARV-766ArvinasPhase 2
Alpha DaRTAlpha Tau MedicalPhase 1/2
Prognostic Genomic TestsEurobio ScientificCommercial
SelinexorKaryopharm TherapeuticsClinical Trials